242 related articles for article (PubMed ID: 36713360)
1.
Yu M; Chang Y; Zhai Y; Pang B; Wang P; Li G; Jiang T; Zeng F
Front Immunol; 2022; 13():1089266. PubMed ID: 36713360
[TBL] [Abstract][Full Text] [Related]
2. Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma.
Peshoff MM; Gupta P; Oberai S; Trivedi R; Katayama H; Chakrapani P; Dang M; Migliozzi S; Gumin J; Kadri DB; Lin JK; Milam NK; Maynard ME; Vaillant BD; Parker-Kerrigan B; Lang FF; Huse JT; Iavarone A; Wang L; Clise-Dwyer K; Bhat KP
Neuro Oncol; 2024 May; 26(5):826-839. PubMed ID: 38237157
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of trem2 promotes proinflammatory microglia and inhibits glioma progression via the JAK2/STAT3 and NF-κB pathways.
Yan Y; Bai S; Han H; Dai J; Niu L; Wang H; Dong Q; Yin H; Yuan G; Pan Y
Cell Commun Signal; 2024 May; 22(1):272. PubMed ID: 38750472
[TBL] [Abstract][Full Text] [Related]
4. TREM2 promotes glioma progression and angiogenesis mediated by microglia/brain macrophages.
Chen X; Zhao Y; Huang Y; Zhu K; Zeng F; Zhao J; Zhang H; Zhu X; Kettenmann H; Xiang X
Glia; 2023 Nov; 71(11):2679-2695. PubMed ID: 37641212
[TBL] [Abstract][Full Text] [Related]
5. TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas.
Zheng J; Wang L; Zhao S; Zhang W; Chang Y; Bosco DB; Huang T; Dheer A; Gao S; Xu S; Ayasoufi K; Al-Kharboosh R; Qi F; Xie M; Johnson AJ; Dong H; Quiñones-Hinojosa A; Wu LJ
Neuro Oncol; 2024 May; 26(5):811-825. PubMed ID: 37941134
[TBL] [Abstract][Full Text] [Related]
6. Molecular and immunological features of TREM1 and its emergence as a prognostic indicator in glioma.
Zhang L; Qu X; Xu Y
Front Immunol; 2024; 15():1324010. PubMed ID: 38370418
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of TREM2 enhances glioma cell proliferation and invasion: a therapeutic target in human glioma.
Wang XQ; Tao BB; Li B; Wang XH; Zhang WC; Wan L; Hua XM; Li ST
Oncotarget; 2016 Jan; 7(3):2354-66. PubMed ID: 26506595
[TBL] [Abstract][Full Text] [Related]
8. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
Front Immunol; 2021; 12():646523. PubMed ID: 33679809
[TBL] [Abstract][Full Text] [Related]
9. CLEC7A regulates M2 macrophages to suppress the immune microenvironment and implies poorer prognosis of glioma.
Wang J; Li X; Wang K; Li K; Gao Y; Xu J; Peng R; Zhang X; Zhang S; Zhou Y; Xu S; Zhang J
Front Immunol; 2024; 15():1361351. PubMed ID: 38846954
[TBL] [Abstract][Full Text] [Related]
10. Distinct roles of TREM2 in central nervous system cancers and peripheral cancers.
Zhong J; Xing X; Gao Y; Pei L; Lu C; Sun H; Lai Y; Du K; Xiao F; Yang Y; Wang X; Shi Y; Bai F; Zhang N
Cancer Cell; 2024 Jun; 42(6):968-984.e9. PubMed ID: 38788719
[TBL] [Abstract][Full Text] [Related]
11. Tumour-associated microglia/macrophages predict poor prognosis in high-grade gliomas and correlate with an aggressive tumour subtype.
Sørensen MD; Dahlrot RH; Boldt HB; Hansen S; Kristensen BW
Neuropathol Appl Neurobiol; 2018 Feb; 44(2):185-206. PubMed ID: 28767130
[TBL] [Abstract][Full Text] [Related]
12. TREM2 mediates MHCII-associated CD4
Zheng J; Wang L; Zhao S; Zhang W; Chang Y; Dheer A; Gao S; Xu S; Ayasoufi K; Al-Kharboosh R; Xie M; Johnson AJ; Dong H; Quiñones-Hinojosa A; Wu LJ
bioRxiv; 2023 Apr; ():. PubMed ID: 37066234
[TBL] [Abstract][Full Text] [Related]
13. IFI30 expression is an independent unfavourable prognostic factor in glioma.
Liu X; Song C; Yang S; Ji Q; Chen F; Li W
J Cell Mol Med; 2020 Nov; 24(21):12433-12443. PubMed ID: 32969157
[TBL] [Abstract][Full Text] [Related]
14. TREM2 Insufficiency Protects against Pulmonary Fibrosis by Inhibiting M2 Macrophage Polarization.
Luo Q; Deng D; Li Y; Shi H; Zhao J; Qian Q; Wang W; Cai J; Yu W; Liu J
Int Immunopharmacol; 2023 May; 118():110070. PubMed ID: 37003186
[TBL] [Abstract][Full Text] [Related]
15. TREM2 knockdown improves the therapeutic effect of PD-1 blockade in hepatocellular carcinoma.
Wang Q; Zheng K; Tan D; Liang G
Biochem Biophys Res Commun; 2022 Dec; 636(Pt 1):140-146. PubMed ID: 36332476
[TBL] [Abstract][Full Text] [Related]
16. TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy.
Molgora M; Esaulova E; Vermi W; Hou J; Chen Y; Luo J; Brioschi S; Bugatti M; Omodei AS; Ricci B; Fronick C; Panda SK; Takeuchi Y; Gubin MM; Faccio R; Cella M; Gilfillan S; Unanue ER; Artyomov MN; Schreiber RD; Colonna M
Cell; 2020 Aug; 182(4):886-900.e17. PubMed ID: 32783918
[TBL] [Abstract][Full Text] [Related]
17. TREM2 as a Potential Immune-Related Biomarker of Prognosis in Patients with Skin Cutaneous Melanoma Microenvironment.
Zhu X; Zeng Z; Chen M; Chen X; Hu D; Jiang W; Du M; Chen T; Chen T; Liao W; Zhang C; Qu Y; Pan W
Dis Markers; 2023; 2023():8101837. PubMed ID: 36741909
[TBL] [Abstract][Full Text] [Related]
18. A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
Zhu Z; Lan Y; Wang L; Ge J; Wang J; Liu F; He Z; Zhang H; Luo M; Lin D; Tan Y; Xu Y; Luo T
BMC Cancer; 2020 Nov; 20(1):1072. PubMed ID: 33167941
[TBL] [Abstract][Full Text] [Related]
19. TREM2: A new player in the tumor microenvironment.
Molgora M; Liu YA; Colonna M; Cella M
Semin Immunol; 2023 May; 67():101739. PubMed ID: 36989543
[TBL] [Abstract][Full Text] [Related]
20. Dual induction of TREM2 and tolerance-related transcript, Tmem176b, in amyloid transgenic mice: implications for vaccine-based therapies for Alzheimer's disease.
Melchior B; Garcia AE; Hsiung BK; Lo KM; Doose JM; Thrash JC; Stalder AK; Staufenbiel M; Neumann H; Carson MJ
ASN Neuro; 2010 Jul; 2(3):e00037. PubMed ID: 20640189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
